The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.
Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings from the Study Suggest:
The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D
Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment
Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors
On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer
Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth
North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine
Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.
Grand View Research has segmented the next generation cancer diagnostics market on the basis of technology, application, cancer type, function, and region:
Technology Outlook (Revenue, USD Million, 2013 - 2024)
Next Generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Application Outlook (Revenue, USD Million, 2013 - 2024)
Cancer Type Outlook (Revenue, USD Million, 2013 - 2024)
Function Outlook (Revenue, USD Million, 2013 - 2024)
Regional Outlook (Revenue, USD Million, 2013 - 2024)
Middle East & Africa
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.